Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke

References

• Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. NICE Clinical Guidelines. No. 127. National Clinical Guideline Centre (UK). London: Royal College of Physicians (UK), 2011
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewsky A, et al. Acute candesartan cilexitil therapy in stroke survivors study group. The ACCESS study: evaluation of acute candesartan cilexitil therapy in stroke survivors. Stroke 2003;34:1699-703
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:1665-83
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-19
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-92
   PubMed Web of Science ®Google Scholar
• Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175.634 patients. J Hypertens 2009; 27:1136-51
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-75
   PubMed Web of Science ®Google Scholar
• Yui Y, Sumiyoshi T, Kodama K, et al.; Japan Multicenter Investigation for Cardiovascular Diseases. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res Clin Exp 2004;27:181-91
   Web of Science ®Google Scholar
• Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish trial in old patients with hypertension – 2. J Hypertens 2000;18:1671-5
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA). a randomized double-blind long-term trial. Circulation 2002;106:2422-7
   PubMed Web of Science ®Google Scholar
• Whitworth JA; World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92
   PubMed Web of Science ®Google Scholar
• Neutel JM, Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Hypertens 2003;1:58-63
   Google Scholar
• Campo C, Saavedra J, Segura J, et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patient. Minerva Med 2005;96:365-71
   PubMedGoogle Scholar
• Omboni S, Zanchetti A. Antihypertension efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensive assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998;16:1831-8
   PubMed Web of Science ®Google Scholar
• Iqbal P1, Stevenson L. Cardiovascular outcomes in patients with normal and abnormal 24-hour ambulatory blood pressure monitoring. Int J Hypertens 2010;2011:786912
   PubMedGoogle Scholar
• Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004;6:621-9
   PubMedGoogle Scholar
• He J, Zhang Y, Xu T, et al.; for the CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014;311:479-89
   PubMed Web of Science ®Google Scholar
• De Simoni A, Hardeman W, Mant J, et al. Trials to improve blood pressure through adherence to antihypertensives in stroke/TIA: systematic review and meta-analysis. J Am Heart Assoc 2013;2:e000251
   PubMed Web of Science ®Google Scholar
• Feldstein CA. Lowering blood pressure to prevent stroke recurrence: a systematic review of long-term randomized trials. J Am Soc Hypertens 2014;8:503-13
   PubMed Web of Science ®Google Scholar
• Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449-72
   PubMed Web of Science ®Google Scholar
• Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1:173-82
   PubMedGoogle Scholar
• Mancia G, Omboni S, Ravogli A, et al. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press 1995;4:148-56
   PubMedGoogle Scholar
• Goda A. Comparative effects of lercanidipine and amlodipine in treatment of mild to moderate hypertension. J Hypertens 2010;28(Suppl A):277-8
   Google Scholar
• Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-6
   PubMed Web of Science ®Google Scholar
• Zanchetti A. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens Suppl 1997;15:S21-5
   PubMedGoogle Scholar
• Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2009;31:1652-63
   PubMed Web of Science ®Google Scholar
• Leonetti G, Magnani B, Pessina AC, et al.; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40
   PubMed Web of Science ®Google Scholar
• Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011;31:561-7
   PubMed Web of Science ®Google Scholar